Big Pharma Oncology Strategies Aim To Treat Cancer Earlier

Combinations May Advance Novel Drugs Faster

ADCs, radiopharmaceuticals, precision medicines and T-cell engagers dominated R&D pipelines reviewed by 12 big pharmas at the first annual AACR Oncology Industry Partnering Event.

A 3D illustration depicting Cancer Cells in the crosshairs, related to cancer treatment
Pharma firms are pursuing new ways of addressing known targets • Source: Shutterstock

Presentations from 12 big pharma companies at a pre-AACR event highlighted common interests in therapeutic modalities that have driven recent dealmaking in the industry – antibody-drug conjugates (ADCs) and radiopharmaceuticals, for instance – and a growing desire to bring novel medicines to earlier lines of cancer treatment sooner. The companies were invited to an inaugural partnering meeting ahead of the American Association for Cancer Research annual conference in San Diego to outline their oncology research and development strategies in a way that might highlight inroads for future collaborators.

Key Takeaways
  • Twelve big pharma companies presented their cancer drug R&D strategies during the inaugural AACR Oncology Industry Partnering Event from 4 to 5 April in San Diego.

The AACR Oncology Industry Partnering Event took place 4-5 April, before the start of the AACR annual meeting on 7...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Anticancer

Kymera Inks CDK2 Deal With Gilead

 

Deal Snapshot: The biotech will receive up to $750m from Gilead for molecular glue degraders against CDK2.

Nuvalent Believes Safety Profile Can Help Zidesamtinib Be ROS-1 Lung Cancer Leader

 

Zidesamtinib would be the fifth ROS-1 targeting therapy on the market, but Nuvalent believes its safety and efficacy profile will make it the best in class.

Exelixis Positions Zanzalintinib For Post-Cabozantinib LOE Future

 

The company announced positive Phase III data in previously treated colorectal cancer for zanzalintinib and it could see sales of more than $1bn in that indication.

J&J’s Trispecific Antibody For Myeloma Offers Improved Safety, Potency Over Bispecifics

 

The drugmaker presented data from its Phase I study of JNJ-79635322 at ASCO and EHA showing a 100% response rate in BCMA- and GPRC5D-naïve patients.

More from Therapy Areas

Biogen’s Spinraza Follow-On May Offer Disease-Modifying Potential

 
• By 

Biogen hopes to move directly from Phase I to Phase III with salanersen, a higher-potency therapy that uses the same mechanism of action as Spinraza.

Kymera Inks CDK2 Deal With Gilead

 

Deal Snapshot: The biotech will receive up to $750m from Gilead for molecular glue degraders against CDK2.

Nuvalent Believes Safety Profile Can Help Zidesamtinib Be ROS-1 Lung Cancer Leader

 

Zidesamtinib would be the fifth ROS-1 targeting therapy on the market, but Nuvalent believes its safety and efficacy profile will make it the best in class.